Content
75%Weight 40%Scale 1-5Reviews the quality of instructions and guidance provided to agents. Good implementation is clear, handles edge cases, and produces reliable results.
A well-constructed investigation workflow: every step has executable tool calls with response parsing, reasoning strategies for interpretation, and fallback paths. The main deductions are a non-executable snippet in the comparison section, a few sentences restating known pharmacology, and the absence of explicit validation checkpoints.
Suggestions
Fix the 'Comparing Two Drugs' snippet: DailyMed_parse_clinical_pharmacology(drug_name=drug[0]) contradicts Step 5's two-step setid process — show the setid resolution or use a tool signature that actually accepts a drug name.
Trim step-intro sentences that restate pharmacology Claude already knows (e.g. 'Most drugs bind more than one target at clinical concentrations', 'Pharmacogenomic variants affect how a patient responds to the drug') to raise conciseness.
Add explicit validation checkpoints between steps (e.g. confirm the ChEMBL ID resolved and the primary target was identified before proceeding to pathway mapping) to strengthen workflow clarity.
Remove DrugBank from the frontmatter description (or add its usage) — the body uses ChEMBL, KEGG, Reactome, STRING, OpenTargets, DailyMed, CPIC, PharmGKB, and PubMed/EuropePMC, but DrugBank never appears.
| Dimension | Reasoning | Score |
|---|---|---|
Conciseness | The body is dense with earning content — executable tu.tools calls, response-parsing loops, reasoning strategies, and a fallback table — and explicitly disclaims teaching known pharmacology ('The LLM already knows drug pharmacology. This skill teaches HOW TO INVESTIGATE'). However, several step intros restate knowledge Claude already has, e.g. 'Most drugs bind more than one target at clinical concentrations' and 'Pharmacogenomic variants affect how a patient responds to the drug', fitting 'Efficient; minor instances of over-explanation that could be trimmed' (4) rather than 5's every-token-earns-its-place. | 4 / 5 |
Actionability | Nearly all guidance is copy-paste-ready with concrete function names, parameters, and parsing of real response shapes (e.g. moa["data"]["drug"]["mechanismsOfAction"]["rows"]). One real gap: the 'Comparing Two Drugs' snippet calls DailyMed_parse_clinical_pharmacology(drug_name=drug[0]), contradicting Step 5's documented two-step setid-based signature, so it is not executable as written. This fits anchor 4 ('concrete code or commands with minor gaps') rather than 5. | 4 / 5 |
Workflow Clarity | A clear 8-step sequence (resolve drug → target → off-target → pathway → label → PGx → literature → integrate) with per-step fallbacks, a consolidated fallback strategies table, and documented known issues ('OpenTargets_get_associated_targets_by_drug_chemblId may fail'). Checkpoints are implicit rather than explicit — there is no 'verify the ChEMBL ID resolved before proceeding' style validation — so it matches anchor 4 ('Clear sequence with most checkpoints present; minor validation gaps') rather than 5. The destructive/batch cap does not apply since this is a read-only investigation workflow. | 4 / 5 |
Progressive Disclosure | No bundle files (references/, scripts/, assets/) exist, so this is a standalone skill; structure is good with numbered step sections, a consistent format, an evidence hierarchy, a report template, and a fallback table. The per-step code is integral to the workflow rather than a separable API reference, fitting anchor 4 ('Good structure; most content is appropriately placed; minor organization gaps') rather than 3, though at ~280 lines a references/ split of tool API details could improve it. | 4 / 5 |
Total | 16 / 20 Passed |